Mesoblast Limited - American Depositary Shares (MESO) closed at $12.45 on November 16, 2026, down 6.2% from the previous close, on volume of 118,547 shares (30-day average 274,606).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Call Spread | 21-Jan-2815 : 25 C | 400 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Mesoblast Showcased at ASX Investor Day
TipRanks (Tue, 17-Nov 6:49 AM ET)
Mesoblast Showcased at ASX Premier Investor Day Event
Globe Newswire (Sun, 15-Nov 6:16 PM ET)
Globe Newswire (Wed, 4-Nov 7:11 PM ET)
Globe Newswire (Sun, 1-Nov 6:46 PM ET)
Market Chameleon (Thu, 29-Oct 4:32 AM ET)
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
Globe Newswire (Wed, 28-Oct 8:19 PM ET)
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Globe Newswire (Thu, 24-Sep 7:00 AM ET)
Mesoblast Reports Substantial Revenue Growth to US$120M
Globe Newswire (Wed, 26-Aug 8:32 PM ET)
Mesoblast Financial Results and Corporate Update Webcast
Globe Newswire (Mon, 24-Aug 7:00 AM ET)
Market Chameleon (Mon, 13-Apr 4:50 AM ET)
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of November 17, 2026, MESO stock price declined to $11.87 with 198,410 million shares trading.
MESO has a beta of 1.53, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.12 to the broad based SPY ETF.
MESO has a market cap of $1.54 billion. This is considered a Small Cap stock.
Last quarter Mesoblast Limited - American Depositary Shares reported $120 million in Revenue and -$.04 earnings per share. This fell short of revenue expectation by $-61 million and exceeded earnings estimates by $.46.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, APIE, QQQS, IBBQ, BIB.
MESO has underperformed the market in the last year with a price return of -19.6% while the SPY ETF gained +9.6%. MESO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.9% and -18.4%, respectively, while the SPY returned -5.9% and -3.1%, respectively.
MESO support price is $11.98 and resistance is $12.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.